Lenvacent 4 mg (Capsule)
Unit Price: ৳ 670.00 (3 x 4: ৳ 8,040.00)
Strip Price: ৳ 2,680.00
Medicine Details
| Category | Details |
|---|---|
| Generic | Lenvatinib mesylate |
| Company | Incepta pharmaceuticals ltd |
| Also available as |
Indications
- Treatment of locally recurrent or metastatic differentiated thyroid cancer
- Treatment of advanced renal cell carcinoma (RCC) following one prior anti-angiogenic therapy
- First-line treatment of unresectable hepatocellular carcinoma (HCC)
- Treatment of advanced endometrial carcinoma
Pharmacology
- Inhibits kinase activities of VEGF receptors
- Inhibits kinases involved in pathogenic angiogenesis and tumor growth
- Exhibits antiproliferative activity in hepatocellular carcinoma cell lines
Dosage
- Recommended dosage for differentiated thyroid cancer (DTC): 24 mg orally once daily
- Recommended dosage for renal cell carcinoma (RCC): 18 mg in combination with 5 mg Everolimus orally once daily
- Recommended dosage for hepatocellular carcinoma (HCC): 12 mg for patients ≥ 60 kg, 8 mg for patients < 60 kg
- Recommended dosage for endometrial carcinoma: 20 mg orally once daily in combination with Pembrolizumab 200 mg
Administration
- Can be swallowed whole or dissolved in liquid
- Dissolving in liquid: put capsules into 1 tbsp of water or apple juice, leave for 10 mins, stir, and drink
Interaction
- Avoid coadministration with drugs that prolong the QT/QTc interval
Contraindications
- Contraindicated in patients with known hypersensitivity to Lenvatinib or any component
Side Effects
- Hypertension
- Cardiac dysfunction
- Arterial thromboembolic events
- Hepatotoxicity
- Renal failure and impairment
- Proteinuria
- Diarrhea
- Fistula formation and gastrointestinal perforation
- QT interval prolongation
- Hypocalcemia
- Reversible posterior leukoencephalopathy syndrome
- Hemorrhagic events
- Impairment of thyroid stimulating hormone suppression/thyroid dysfunction
- Wound healing complications
Pregnancy & Lactation
- Can cause embryo-fetal harm
- Females of reproductive potential should use effective contraception
- Discontinue breastfeeding during treatment with Lenvatinib and for at least 1 week after the last dose
Precautions & Warnings
- Hypertension monitoring and control
- Cardiac dysfunction monitoring
- Arterial thromboembolic event management
- Hepatotoxicity monitoring
- Renal failure or impairment management
- Proteinuria monitoring
- Diarrhea management
- Fistula formation and gastrointestinal perforation management
- QT interval prolongation correction
- Hypocalcemia management
- Reversible posterior leukoencephalopathy syndrome management
- Hemorrhagic events risk assessment
- Thyroid stimulating hormone suppression/thyroid dysfunction monitoring
- Wound healing complications assessment
Use in Special Populations
- Dosage modifications for severe renal impairment: 14 mg orally once daily for DTC, 10 mg orally once daily for RCC and endometrial carcinoma
- Dosage modifications for severe hepatic impairment: 14 mg orally once daily for DTC, 10 mg orally once daily for RCC and endometrial carcinoma
- Safety and effectiveness in pediatric patients not established
Overdose Effects
- Not expected to be dialyzable
- Death occurred in a patient who received a single dose of 120 mg orally
Storage Conditions
- Store below 30°C in a dry place
- Protect from light
- Keep out of the reach of children